SENSIPAR ANTITRUST

In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation, Case Nos. 1:19-md-02895-LPS/1:19-cv-396-LPS/1:19-cv-1461-LPS (D. Del.)

On February 26, 2019, Chimicles Schwartz Kriner & Donaldson-Smith LLP (“CSK&D”) and its co-counsel filed a class action complaint in the United States District Court for the District of Delaware against drug companies Amgen, Teva, Watson and Actavis related to the drug Sensipar. Sensipar is a calcium-sensing receptor agonist indicated for secondary hyperparathryroidism (“HPT”) in adult patients with chronic kidney disease on dialysis. The complaint, which asserts antitrust claims under the Sherman Act, alleges that these entities engaged in an anticompetitive scheme to delay the entry of lower-priced generic Sensipar, thereby raising the price of the drug. The complaint seeks to represent a class of persons and entities that purchased Sensipar directly from Amgen on or after March 8, 2018. On July 15, 2019, CKS&D were appointed Interim Delaware Liaison Counsel for the proposed class, and on September 13, 2019, filed a Consolidated Class Action Complaint to add allegations gleaned from documents received through discovery. A copy of the operative Complaint can be accessed below.

On October 15, 2019, Defendants moved to dismiss the operative complaint. Defendants’ motions have been fully briefed, and the Court will hold oral argument on April 28, 2020. The parties are also engaged in discovery.